Global Auto-Injectors market is expected to witness a CAGR of 20.7% during the forecast period. Certain factors that are driving the market growth include increasing demand for the convenience of patients, rising incidence of chronic and lifestyle diseases, and technological advancements.
The use of auto-injector has brought many benefits for both the patient and healthcare professional. It has simplified self-administration, reduced anxiety, improved safety, and improved compliance. For instance, most of the currently available disease-modifying therapies available in the market for the treatment of multiple sclerosis are administered through injection. This has always been considered as a source of fear for a large number of patients and a considerable cause of non-adherence to treatment. Autoinjectors can address this issue by ensuring that the injection is made at the accurate depth and can distinctly improve the comfort and tolerability of administration when compared to manual syringes. Data from various clinical trials support the use of autoinjectors presenting that they improve adherence and the smaller gauge needles significantly reduce injection discomfort.
Key Market Trends
Rheumatoid Arthritis is Expected to Hold Significant Market Share in the Application Segment
Rheumatoid arthritis (RA) is a chronic autoimmune disorder in which the joints are attacked by the body’s immune system and inflammation of the synovium is created, causing swelling and pain in and around the joints. The RA Organisation, US, states that the disease affects over 1.3 million Americans and as much as 1% of the worldwide population (as of 2018).
According to several recent studies, majority of the patients with rheumatoid arthritis who used an autoinjector for the treatment were observed to be comfortable using the device and even had better outcomes than those who had someone else administer injections.
North America Dominates the Market and Expected to do Same in the Forecasted Period
Several epinephrine auto-injectors are now available in the region. There are generic versions as well. Each contains the drug epinephrine. But, each device possesses its own unique set of instructions for use. Understanding the differences is essential so that one can get the device one wants and knows how to properly use it. In the region, children with severe allergies now have access to a new generic version of EpiPen and EpiPen Jr. Epinephrine auto-injectors. The US Food and Drug Administration (FDA) granted approval to Teva Pharmaceutical Industries Ltd., in 2018, to market the generics in 0.3 milligrams (mg) and 0.15 mg strengths.
The global Auto-Injectors market is highly competitive and consists of a number of major players. Companies like Abbvie, Amgen, AstraZeneca, Bayer, Becton, Dickinson and Company, Biogen, Eli Lilly, Novartis, Teva Pharmaceuticals, Ypsomed, among others, hold the substantial market share in the Auto-Injectors market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support